11/13/2023

Diltiazem Hydrochloride Injection

Products Affected - Description

- Diltiazem Hydrochloride injection, Hikma, 5 mg/mL, 25 mL vial, 10 count, NDC 00641-6015-10
- Diltiazem Hydrochloride injection, Hikma, 5 mg/mL, 5 mL vial, 10 count, NDC 00641-6013-10
- Diltiazem Hydrochloride injection, Sagent, 5 mg/mL, 10 mL vial, 10 count, NDC 70860-0301-10
- Diltiazem Hydrochloride injection, Sagent, 5 mg/mL, 25 mL vial, 10 count, NDC 70860-0301-25
- Diltiazem Hydrochloride injection, Sagent, 5 mg/mL, 5 mL vial, 10 count, NDC 70860-0301-05

Reason for the Shortage

- Akorn discontinued diltiazem injection in mid-2022.
- Athenex divested diltiazem to Sagent in June 2023.
- Eugia launched diltiazem injection in June 2023.
- Hikma did not provide a reason for the shortage.
- Pfizer did not provide a reason for the shortage. They discontinued the 5 mL vials in early-2021. The 10 mL vials were discontinued in September 2021.

Available Products

- Diltiazem Hydrochloride injection, Eugia US, 5 mg/mL, 10 mL vial, 10 count, NDC 55150-0426-10
- Diltiazem Hydrochloride injection, Eugia US, 5 mg/mL, 25 mL vial, 10 count, NDC 55150-0427-10
- Diltiazem Hydrochloride injection, Eugia US, 5 mg/mL, 5 mL vial, 10 count, NDC 55150-0425-10
- Diltiazem Hydrochloride injection, Hikma, 5 mg/mL, 10 mL vial, 10 count, NDC 00641-6014-10
- Diltiazem Hydrochloride lyophilized powder for solution for injection, Pfizer, 100 mg, ADD-Vantage vial, 10 count, NDC 00409-4350-03

Estimated Resupply Dates

- Hikma has diltiazem 5 mg/mL 5 mL and 25 mL vials on back order and the company cannot estimate a release date.
- Sagent has diltiazem 5 mg/mL 5 mL and 25 mL vials on allocation.

Updated

Updated November 13, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 25, 2015 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.